Hypotensive Drugs
PreclinicalSmall molecule
Hypotensive Drugs is one of 13 small molecule programs targeting Adenoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
15 competitors in Adenoma
#DrugCompanyPhaseTrials
1Dostinex
PfizerApproved
Nolvadex
AstraZenecaApproved
Orilissa
AbbVieApproved
Duragesic
CCephalon
Approved
Avandia
Jazz PharmaceuticalsPreclinical
Biaxin
AbbViePreclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ultram
WWim Janssens
Preclinical
Drug Treatment
BBiosense Webster, Inc.
Preclinical
FET-PET/MRI
UUniversity of Alabama at Birmingham
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2030
Recruiting
Adenoma
NCT05991856
Clinical
Trials by Indication[1]
Adenoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hypotensive Drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details